Ireland
--:--IST
Recruiting Observational

MRI-Based Lesion Differentiation in Older Patients With Multiple Sclerosis

NCT07444047 · tracked via the Priya Life Science Norway tracker
Phase
Observational
Started
2026-05-11
Last updated
2026-06-01

Condition(s) studied

Multiple Sclerosis (MS)Cerebral Small Vessel Diseases

Study summary

This study investigates whether an advanced MRI technique called Quantitative Susceptibility Mapping (QSM) can improve the differentiation of white matter lesions in people aged 50-70 years with multiple sclerosis (MS). In older individuals with MS, white matter changes seen on MRI may be related to MS or to other types of white matter changes, most commonly age-related changes or chronic small vessel disease. These conditions can appear similar on conventional MRI scans, making interpretation challenging.

Participants will undergo routine clinical MRI, including a short additional QSM sequence, as well as brief cognitive and physical assessments. A comparison group with cerebral small vessel disease will also be included.

The goal of the study is to determine whether QSM can provide more precise lesion characterization and support more accurate clinical interpretation of MRI findings in older patients with MS.

Eligibility

Sex
ALL
Min age
50 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria Multiple Sclerosis (MS) cohort (AgeMS): * Age 50-70 years * Clinically confirmed diagnosis of multiple sclerosis * Participation in the AgeMS study at Oslo University Hospital Inclusion Criteria Cerebral Small Vessel Disease (cSVD) control cohort: * Age 50-80 years * Radiological evidence of hypertensive small vessel disease on MRI * Good clinical recovery following transient ischemic attack (TIA), minor stroke, or stroke mimic diagnosis Exclusion Criteria Multiple Sclerosis (MS) cohort: * MRI contraindications * Severe psychiatric comorbidity * Major functional disability unrelated to MS or CSVD Exclusion Criteria Cerebral Small Vessel Disease (cSVD) control cohort: * MRI contraindications * Probable or definite cerebral amyloid angiopathy according to Boston criteria 2.0 * Genetic or inflammatory vasculopathies * Persistent neurological deficits * Severe psychiatric comorbidity * Major functional disability unrelated to CSVD

Primary outcome measure(s)

  • Lesion-Level Quantitative Susceptibility (ppb) Within T2 FLAIR Hyperintense White Matter Lesions at Baseline — Baseline MRI (single MRI session for both cohorts)
    Quantitative susceptibility (ppb) will be measured using QSM within each segmented T2 FLAIR hyperintense white matter lesion. Lesion-level susceptibility values will be compared between lesions from the MS cohort and the cSVD cohort. Statistical analyses will account for clustering of multiple lesions within individual participants.

Trial sites (1)

FacilityCityRegionStatus
Oslo University Hospital Oslo Oslo Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07444047 on ClinicalTrials.gov ↗ ← All trials in Norway